Healthcare provider profile · identity verified

Eric A Rudin, M.D.

Endocrinology · KATONAH, NY · NPI 1801858196

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	1281	308
Metformin Hcl Er	Metformin Hcl	648	179
Mounjaro	Tirzepatide	488	103
Metformin Hcl	Metformin Hcl	473	129
Ozempic	Semaglutide	472	112
Synthroid	Levothyroxine Sodium	436	110
Alendronate Sodium	Alendronate Sodium	426	128
Jardiance	Empagliflozin	423	100
Glipizide Er	Glipizide	405	117
Rosuvastatin Calcium	Rosuvastatin Calcium	345	90
Atorvastatin Calcium	Atorvastatin Calcium	290	77
Glimepiride	Glimepiride	246	74
Losartan Potassium	Losartan Potassium	214	58
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	208	63
Farxiga	Dapagliflozin Propanediol	175	46
Amlodipine Besylate	Amlodipine Besylate	158	47
Januvia	Sitagliptin Phosphate	141	39
Lisinopril	Lisinopril	130	40
Ezetimibe	Ezetimibe	113	33
Pravastatin Sodium	Pravastatin Sodium	102	30
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	100	42
Trulicity	Dulaglutide	96	33
Metoprolol Succinate	Metoprolol Succinate	91	26
Gabapentin	Gabapentin	90	29
Humalog Kwikpen U-100	Insulin Lispro	80	27
Risedronate Sodium	Risedronate Sodium	78	26
Tradjenta	Linagliptin	75	21
Pioglitazone Hcl	Pioglitazone Hcl	73	18
Novolog Flexpen	Insulin Aspart	72	24
Hydrochlorothiazide	Hydrochlorothiazide	71	27
Tresiba Flextouch U-100	Insulin Degludec	70	21
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	66	28
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	65	13
Methimazole	Methimazole	64	21
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	63	18
Ramipril	Ramipril	62	19
Fenofibrate	Fenofibrate Nanocrystallized	56	15
Rybelsus	Semaglutide	56	13
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	55	17
Valsartan	Valsartan	53	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	52	23
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	52	13
Prolia	Denosumab	49	32
Simvastatin	Simvastatin	46	14
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	44	13
Humalog	Insulin Lispro	43	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	suppressed
Ibandronate Sodium	Ibandronate Sodium	36	15
Repatha Sureclick	Evolocumab	35	suppressed
Hydrocortisone	Hydrocortisone	34	suppressed
Testosterone	Testosterone	33	17
Testosterone Cypionate	Testosterone Cypionate	33	12
Liothyronine Sodium	Liothyronine Sodium	31	suppressed
Nifedipine Er	Nifedipine	30	suppressed
Calcitriol	Calcitriol	26	suppressed
Novolog	Insulin Aspart	26	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Spironolactone	Spironolactone	23	suppressed
Victoza 3-Pak	Liraglutide	22	suppressed
Carvedilol	Carvedilol	21	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Icosapent Ethyl	Icosapent Ethyl	20	suppressed
Invokana	Canagliflozin	20	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	15	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Armour Thyroid	Thyroid,pork	14	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Prednisone	Prednisone	12	suppressed
Sandostatin Lar Depot	Octreotide Acetate,mi-Spheres	12	suppressed
Genotropin	Somatropin	11	suppressed
Glipizide	Glipizide	11	suppressed
Risedronate Sodium Dr	Risedronate Sodium	11	suppressed
Sertraline Hcl	Sertraline Hcl	11	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error